시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
HER2 저발현 위 또는 위식도 접합부(GEJ) 선암 시장 : 1차 조사(KOL의 인사이트) - 시장 인텔리전스 - 역학과 시장 예측(-2034년)
HER2-Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | Primary Research (KOL´s Insight) | Market Intelligence | Epidemiology & Market Forecast-2034
상품코드 : 1349828
리서치사 : Mellalta Meets LLP
발행일 : On Demand Report
페이지 정보 : 영문 200 Pages
 라이선스 & 가격 (부가세 별도)
US $ 6,989 ￦ 9,716,000
PPT (Single User License) help
PPT 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄는 1회에 한해 가능하며, PPT 내 텍스트 등의 Copy 가능합니다. 인쇄물의 이용 범위는 PPT 이용 범위에 준합니다.
US $ 10,484 ￦ 14,575,000
PPT (2 - 3 User License) help
PPT 보고서를 3명만 이용할 수 있는 라이선스입니다. 인쇄는 3회에 한해 가능하며, PPT 내 텍스트 등의 Copy 가능합니다. 인쇄물의 이용 범위는 PPT 이용 범위에 준합니다.
US $ 13,978 ￦ 19,433,000
PPT (Site License - Up to 10 Users) help
PPT 보고서를 10명만 이용할 수 있는 라이선스입니다. 인쇄는 10회에 한해 가능하며, PPT 내 텍스트 등의 Copy 가능합니다. 인쇄물의 이용 범위는 PPT 이용 범위에 준합니다.
US $ 20,967 ￦ 29,150,000
PPT (Enterprise License) help
PPT 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며, PPT 내 텍스트 등의 Copy 가능합니다. 인쇄물의 이용 범위는 PPT 이용 범위에 준합니다.


한글목차

HER2 저발현 위 또는 위식도 접합부(GEJ) 선암 시장은 화학요법, 면역요법, 표적치료제가 크게 기여하고 있으며, 2034년까지 새로운 신흥 치료제의 도입이 HER2 저발현 위 또는 위식도 접합부(GEJ) 선암 치료제 시장에 극적인 변화를 초래하는 주요 돌파구가 될 것으로 예상됩니다. 포인트가 될 것으로 예상됩니다.

전문가들은 위암 및 기타 여러 암이 HER2를 발현하고 HER2 표적치료제에 반응할 수 있다고 생각합니다. 따라서 이러한 암, 특히 HER2 발현이 낮은 환자에서 T-DXd의 사용에 대한 연구에 대한 관심이 높아지고 있습니다.

위 및 위식도 접합부(GEJ) 선암은 치료 옵션이 제한적인 침습성 악성 종양으로, HER2 저발현 종양은 면역조직화학(IHC) 분석에서 1점 또는 IHC 스코어2에서 in situ hybridization(ISH) 음성으로 정의됩니다. 이 종양의 하위 집합은 위 또는 GEJ 선암에서 충분히 특징이 밝혀지지 않았으며, 그 임상적 의미는 아직 명확하지 않습니다. 그러나 최근 증거에 따르면 HER2 저발현이 예후에 영향을 미치고 치료 결정의 지침이 될 수 있음을 시사하고 있습니다.

HER2 저발현 위 또는 위식도 접합부 선암 환자들은 치료 선택에 있으며, 어려움을 겪고 있습니다. 트루스투주맙과 같은 기존의 HER2 표적치료제는 이 환자군에서 제한적인 효과만을 보여주었습니다. 따라서 이들 환자의 결과를 개선하기 위해 대체 치료 전략을 고려해야 합니다.

세계의 HER2 저발현 위 또는 위식도 접합부(GEJ) 선암 시장에 대해 조사했으며, 시장 현황과 함께 증례수의 동향, 환자 동향, 경쟁 제품 시장 포지셔닝, 시장의 기회 등을 제공하고 있습니다.

목차

제1장 주요 요약

제2장 HER2 저발현 위 또는 위식도 접합부(GEJ) 선암 질환 배경

제3장 HER2 저발현 위 또는 위식도 접합부(GEJ) 선암 진단

제4장 현재의 치료법과 의료 행위

제5장 미충족 요구

제6장 새로운 치료법

제7장 HER2 저발현 위 또는 위식도 접합부(GEJ) 선암 출시 스케줄과 주요 시장 이벤트

제8장 HER2 저발현 위 또는 위식도 접합부(GEJ) 선암 - 가격과 상환

제9장 KOL 인사이트(미국, EU, 일본)

제10장 향후 치료 패러다임

제11장 시장 전망

제12장 시장 촉진요인과 억제요인

제13장 부록

제14장 조사 방법

KSA
영문 목차

영문목차

The HER2-Low Gastric / Gastroesophageal Junction (GEJ) Adenocarcinoma market is hugely contributed by chemotherapy, immunotherapy, and targeted therapies. By 2034, the uptake of novel emerging therapies will serve as a major breakpoint to get a drastic change in the HER2-Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma therapeutics market.

"Experts believe that gastric cancer and some other cancers express HER2 and respond to HER2-targeted therapies. This has led to a growing interest in studying the use of T-DXd in these cancers, particularly in patients with low expression of HER2."

Gastric and gastroesophageal junction (GEJ) adenocarcinomas are aggressive malignancies with limited treatment options. HER2-low tumors are defined as having a score of 1+ on immunohistochemical (IHC) analysis or an IHC score of 2+ with negative results on in situ hybridization (ISH). This subset of tumors has not been well characterized in gastric or GEJ adenocarcinomas, and their clinical significance remains unclear. However, recent evidence suggests that HER2-low expression may have prognostic implications and could potentially guide treatment decisions.

Patients with HER2 low gastric or gastroesophageal junction adenocarcinoma pose a challenge in terms of treatment selection. Traditional HER2-targeted therapies, such as trastuzumab, have shown limited efficacy in this subgroup. Therefore, alternative treatment strategies need to be explored to improve outcomes for these patients.

Mellalta's HER2-Low Gastric / Gastroesophageal Junction (GEJ) Adenocarcinoma Report- Market Summary

Report Attributes Details
Market Size 2034: $ billion
Key Market Players: Duality Biologics; AstraZeneca/Daiichi Sankyo
Forecast Period: 2020-2034.
Countries Covered: US, France, Germany, Italy, Spain, UK, China and Japan.
Current SOC Chemotherapy: Immunotherapy; Targeted Therapies.
Future SOC: Targeted Therapies; Combination Approach.
Key Unmet Need: Improved HER2 Assessment; Limited Treatment Option.
Key Clinical Insights: The poor prognosis observed in patients with HER2-low gastric or GEJ adenocarcinoma highlights the need for novel treatment approaches and pharmaceutical companies are now exploring the development of novel agents specifically designed to address the needs of this patient population.
Provider-Patient (PPP) Perspective: Cost-effectiveness of treatment; Better Diagnostic Identification; Access to appropriate treatments and improved options.

Mellalta's HER2-Low Gastric / Gastroesophageal Junction (GEJ) Adenocarcinoma Report - Epidemiology

The total incident cases of HER2-Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma in the G7 countries are anticipated to increase by a significant number of cases by 2034 for the study period (2020-2034). As per estimates, the United States will present with the highest incidence of HER2-Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma cases in 2034. Among the EU5, Germany had the highest HER2-Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma cases, followed by the UK, France, Italy, and Spain. Japan is reported to have the highest number of treated cases after the United States, Germany, and the UK.

A retrospective study evaluated HER-2 expression in early-stage gastric cancer using immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) and found that 8.3% of patients had HER2-positive tumors, 31.8% had HER2-low tumors, and 50.3% had HER2-negative tumors.

Mellalta's HER2-Low Gastric / Gastroesophageal Junction (GEJ) Adenocarcinoma Report - Current Market Size & Forecast Trends

The current standard of care is limited to chemotherapy, immunotherapy, and targeted therapy. Recent developments have shown that ADCs, such as DS-8201 and Disitamab vedotin, release intracellular toxins that can exert a killing effect on neighboring cells without target expression. This bystander effect allows patients with HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma to benefit from HER2-targeted therapy. Therefore, ADCs may expand the population that can benefit from HER2-targeted therapy and are expected to be a novel option for patients whose tumors have low HER2 expression.

The advent of anti-HER2 therapies, such as trastuzumab and trastuzumab deruxtecan (T-DXd), has revolutionized the treatment landscape for HER2-positive gastric or gastroesophageal junction adenocarcinoma. However, the efficacy of these therapies in HER2-low tumors remains uncertain. Recent studies have shown promising results with T-DXd in patients with HER2-low gastric cancer, suggesting that HER2-low tumors may still benefit from HER2-targeted treatments. Based on the results of the DESTINY-Gastric01 trial, T-DXd was approved in Japan for the treatment of patients with HER2-positive unresectable advanced or recurrent gastric cancer that has progressed after chemotherapy. T-DXd is now recommended in the Japanese Gastric Cancer Association treatment guidelines as the third-line treatment for HER2-positive gastric cancer. Additional studies on T-DXd for the treatment of AGC are also ongoing. The DESTINY-Gastric02 trial (NCT04014075) is an open-label, single-arm phase II trial to assess the efficacy and safety of T-DXd in HER2-positive AGC patients who have been treated with previous trastuzumab containing chemotherapy in non-Asian populations. The primary endpoint is the ORR by independent central review, similar to the DESTINY-Gastric01 trial. Seventy-two patients will be enrolled.

Mellalta Meets Current Treatment Strategies in Gastric Cancer

Current Treatment Strategies in Gastric Cancer Source: Daisuke Kotani et al 2021

In the 2024-2034 forecast period, there will be tremendous growth and shift in therapeutic market with the launch of novel emerging therapies like DB-1303 (Duality Biologics), Trastuzumab deruxtecan (AstraZeneca/Daiichi Sankyo), and more. We expect a greater uptake of the new therapies which will result in better treatment outcomes for HER2-Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma market space. The launch of these upcoming therapies will drive the highly competitive therapeutic market in the coming time.

Questions Answered:

Report Highlights:

Table of Content

1. Executive Summary

2. HER2-Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Disease Background

3. HER2-Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma-Diagnosis

4. Current Therapy and Medical Practice

5. Unmet Needs

6. Emerging Therapy

7. Launch Timeline & Key Market Events for HER2-Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

8. HER2-Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma - Pricing & Reimbursement

9. KOLs Insight (US, EU, JP)

10. Future Treatment Paradigm

11. Market Outlook

12. Market Drivers and Constraints

13. Appendix

14. Methodology

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기